November 1, 2015
Molecular Subtyping Improves Diagnostic Stratification of Patients with Primary Breast Cancer into Prognostically-Defined Risk Groups
Breast Cancer Res Treat (2015) 154: 81. https://doi.org/10.1007/s10549-015-3587-9.
Katharine Yao, Robert Goldschmidt, Mary TurkJelle Wesseling, Lisette Stork-Sloots, Femke de Snoo, Massimo Cristofanilli
Retrospective, observational study comparing MP+BP subtyping with long-term outcomes: MammaPrint low-risk patients had a 10-year DMFS of 96 % (95 %CI 92.8–99.4), while MammaPrint high-risk patients had a 10-year DMFS of 87%.